ClinicalTrials.gg
Status unknownNCT05066646FUMANBA-1Updated Nov 23, 2021

A Phase 1/2 Study of a Fully Human BCMA-targeting CAR (CT103A) in Patients With Relapsed/Refractory Multiple Myeloma (FUMANBA-1)

A Phase 1/2 interventional study of CT103A in Multiple Myeloma, sponsored by Nanjing IASO Biotechnology Co., Ltd.. Status unknown at 14 sites in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2021-11-23.

Sponsored by Nanjing IASO Biotechnology Co., Ltd. · Phase 1/2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Sep 2021), so the status shown — last known as Recruiting — may be out of date.

From the registry’s dates

  • Registered 1 year 5 months after the study started (first participant enrolled Apr 2020, registered Sep 2021).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
132
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 448 studies in Multiple Myeloma with a site in China — 238 open to participants now, 275 under way, 47 of them phase 3. Multiple Myeloma · China.

Planned enrollment
79th of 406
132 · median 40
Started
2020
with 24 others
Phase 1/2
65 of 448
43 open now
Registered
158th of 448
by date

Among the 448 studies in Multiple Myeloma with a site in China, this one is the 79th largest by planned enrollment of the 406 interventional ones that give a count, is one of 25 that started in 2020, is one of 65 in phase 1/2, and was the 158th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

238 of the 448 studies in Multiple Myeloma with a site in China are open now. Recruiting first, the newest first:

233 more — sign in →

All 238 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 448 studies in Multiple Myeloma with a site in China, or all of them as a file.
02

Study summary

This study is a single-armed, open-label, multicenter Phase 1/2 study to evaluate the efficacy and safety of CT103A in subjects with relapsed and refractory MM.

Read the detailed description

Leukapheresis procedure will be performed to manufacture CT103A chimeric antigen receptor (CAR) modified T cells. Bridging therapy is allowed between PBMC collection and lymphodepletion. Lymphodepletion with fludarabine and cyclophosphamide was performed for three consecutive days. After 1-day rest, subjects will receive a single dose infusion of CT103A at 1.0 x 10\^6 CAR+ T cells/Kg. Subjects will be followed in the study for a minimum of 2 years after CT103A infusion. Long-term follow-up for lentiviral vector safety will be followed for up to 15 years after CT103A infusion.

03

Conditions studied

  • Multiple Myeloma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects must satisfy all the following criteria to be enrolled in the study:

  1. age 18 to 70 years old, male or female.
  2. Subjects with diagnosed MM according to IMWG criteria and have had at least 3 including chemotherapy based on proteasome inhibitors (PIs) and immunomodulatory agents (IMiDs). Disease progression must be documented during or within 12 months following the most recent anti-myeloma treatment.
  3. Evidence of cell membrane BCMA expression, as determined by a validated immunohistochemistry (IHC) or flow cytometry of tumor tissue (e.g., bone marrow , or plasmacytoma).
  4. The subjects should have based on at least one of the following parameters:

    • The proportion of primitive immature or monoclonal plasma cells detected by bone marrow cytology, bone marrow biopsy, or flow cytometry is ≥ 5%.
    • Serum M-protein ≥ 0.5 g/dL.
    • Urine M-protein ≥ 200 mg/24 hrs.
    • For those whose Serum or Urine M-protein does not meet the measurable criteria but the light chain type, serum free light chain (sFLC): involved sFLC level ≥ 10 mg/dL (100 mg/L) provided serum FLC ratio is abnormal.
  5. performance score 0-1.
  6. Estimated ≥ 12 weeks.
  7. Patients should have adequate organ function:

    • Hematology: (ANC) ≥1×10\^9 /L (prior use of growth factor support is permitted, but subjects must not have received supportive treatment within 7 days prior to laboratory examination); absolute lymphocyte count (ALC) ≥0.3×10\^9 /L; ≥50×10\^9 /L (subjects must not have received blood transfusion support within 7 days prior to laboratory examination); ≥60 g/L (subjects must not have received transfusion of red blood cells [RBC] within 7 days prior to laboratory examination; the use of recombinant human erythropoietin is permitted).
    • Liver function: (ALT) and aspartate aminotransferase (AST) ≤ 2.5× (ULN); total serum ≤ 1.5×ULN.
    • Renal function: rate (CrCl) calculated according to Cockcroft-Gault formula ≥ 40 ml/min.
    • Coagulation function: Fibrinogen ≥ 1.0 g/L; (APTT) ≤ 1.5×ULN, prothrombin time (PT) ≤ 1.5×ULN.
    • SpO2 > 91%.
    • (LVEF) ≥ 50%.
  8. The subject and his/her spouse agree to use an effective tool or medication (excluding safety period contraception) for one year from the date of the subject's to the date of CAR T cell infusion.
  9. Subject must sign the informed consent form approved by ethics board in person before starting any screening procedure.

Exclusion criteria

Exclusion Criteria:

The presence of any of the following will exclude a subject from enrollment:

  1. Subjects who are known to have or need long-term therapy.
  2. Subjects have received an hematopoietic stem cell transplantation (auto-HSCT) within 12 weeks before leukapheresis or have a previous history of two times of allo-HSCT or previous history of an allogeneic hematopoietic stem cell transplantation (allo-HSCT).
  3. Insufficient mononuclear cells for CAR T cell production.
  4. Subjects have received any anti-cancer treatment as follows: targeted therapies, epigenetic therapy or invasive experimental instruments therapy within 14 days or at least 5 half-lives before leukapheresis (according to the longer time), or monoclonal antibody for treating multiple myeloma within 21 days before leukapheresis, or cytotoxic therapy or proteasome inhibitors within 14 days before leukapheresis, or immunomodulatory agents within 7 days before leukapheresis.
  5. Subjects who were receiving a used therapeutic dose of treatment (defined as prednisone or equivalent > 20mg) within 7 days prior to screening, except for physiological alternatives, inhalation, or topical use.
  6. Subjects with serious heart disease: including but not limited to unstable angina, myocardial infarction (within 6 months prior to screening), congestive heart failure ( classification ≥III), and severe arrhythmias.
  7. Subjects with systemic diseases that the investigator determined to be unstable include, but are not limited to, severe liver and kidney or metabolic diseases requiring medical treatment.
  8. Subjects with second in addition to MM within the past 5 years before the screening, exceptions to this criterion: successfully treated cervical carcinoma in situ and non- basal or squamous cell skin carcinoma, local prostate cancer after radical surgery, and ductal carcinoma in situ of the breast after radical surgery.
  9. Subjects with a history of organ transplantation.
  10. Subjects have central nervous system (CNS) involvement (including cranial neuropathies or mass lesions and ).
  11. Subjects with extramedullary lesions (except for a single extramedullary lesion with a maximum transverse diameter of 3 cm).
  12. Subjects with plasma cell leukemia.
  13. Subjects have received major surgery within 2 weeks prior to leukapheresis or plan to receive surgery during the study or within 2 weeks after the study treatment (excluding local anesthesia).
  14. Subjects participated in another interventional clinical study 3 months before signing the (ICF);
  15. Subjects with any uncontrolled active infection needed to receive systemic therapy within 7 days before leukapheresis collection (excluding \< grade 2 urogenital infection and upper respiratory infection).
  16. Positive for any of the following tests:

    • virus (HBV) surface antigen (HBsAg) or hepatitis B core antibody-positive and detectable HBV DNA in peripheral blood
    • virus (HCV) antibody and hepatitis C virus RNA in peripheral blood
    • (HIV) antibody
    • Cytomegalovirus (CMV) DNA
    • Treponema Pallidum antibody
  17. Pregnant or lactating women.
  18. Subjects with mental illness or consciousness disorder or disease of the central nervous system
  19. Subjects who haven't recovery to Grade 1 or baseline of any toxicities due to prior treatments, excluding alopecia.
  20. Other conditions that researchers consider inappropriate for inclusion.
Terms in these criteria, in plain language(29)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
132 participants (estimated)

Study arms

  • Experimental
    CT103A in relapsed and refractory multiple myeloma patients

    CT103A autologous CAR-T cells will be infused at RP2D of 1.0 x 10\^6 CAR+ T cells after receiving lymphodepleting chemotherapy

    Drug: CT103A

Interventions

  • DrugCT103A

    CT103A consists of autologous T lymphocytes transduced with anti-BCMA CAR lentiviral vector that containing a unique CAR structure with a fully human single-chain variable fragment (scFv).

06

What researchers measure

Primary outcomes

  1. Phase 1: Incidence and Severity of Adverse Events

    An adverse event is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product.

    Time frame: Minimum of 2 years post CT103A infusion

  2. Phase 1: Laboratoty tests

    Abnormal results of laboratoty tests

    Time frame: Minimum of 2 years post CT103A infusion

  3. Phase 1: Vital signs

    Abnormal results of vital signs

    Time frame: Minimum of 2 years post CT103A infusion

  4. Phase 1: Physical examination

    Abnormal results of physical examination

    Time frame: Minimum of 2 years post CT103A infusion

  5. Phase 2: Overall response rate (ORR) evaluated by an Independent Review Committee (IRC)

    Percentage of subjects who achieved partial response (PR) or better according to IMWG Uniform Response Criteria for Multiple Myeloma as assessed by an IRC

    Time frame: 3 months post CT103A infusion

Secondary outcomes

  1. Overall response rate (ORR) evaluated by the investigators

    Percentage of subjects who achieved partial response (PR) or better according to IMWG Uniform Response Criteria for Multiple Myeloma as assessed by the investigators

    Time frame: 3 months post CT103A infusion

  2. Overall Survival (OS)

    Time from CT103A infusion to time of death due to any cause

    Time frame: Minimum of 2 years post CT103A infusion

  3. Duration of Response (DOR)

    Time from first response evaluated by an IRC or investigators to disease progression or death from any cause

    Time frame: Minimum of 2 years post CT103A infusion

  4. Progression-free Survival (PFS)

    Time from CT103A infusion to first documentation of progressive disease (PD), or death due to any cause, whichever occurs first

    Time frame: Minimum of 2 years post CT103A infusion

  5. Time to Response (TTR)

    Time from CT103A infusion to first documentation of response evaluated by an IRC or investigators

    Time frame: Minimum of 2 years post CT103A infusion

  6. Laboratoty tests

    Abnormal results of laboratoty tests

    Time frame: Minimum of 2 years post CT103A infusion

  7. Vital signs

    Abnormal results of vital signs

    Time frame: Minimum of 2 years post CT103A infusion

  8. Physical examination

    Abnormal results of physical examination

    Time frame: Minimum of 2 years post CT103A infusion

  9. Minimal Residual Disease (MRD)

    Proportion of subjects who achieved MRD negative

    Time frame: Minimum of 2 years post CT103A infusion

  10. Pharmacokinetics - Cmax

    The maximum transgene level at Tmax

    Time frame: Minimum of 2 years post CT103A infusion

  11. Pharmacokinetics - Tmax

    Time to peak transgene level

    Time frame: Minimum of 2 years post CT103A infusion

  12. Pharmacokinetics - AUC0-28days

    Area under the curve of CAR T cells from time zero to Day 28

    Time frame: Minimum of 2 years post CT103A infusion

  13. Pharmacokinetics - AUC0-90days

    Area under the curve of CAR T cells from time zero to Day 90

    Time frame: Minimum of 2 years post CT103A infusion

  14. soluble BCMA levels

    soluble BCMA levels in peripheral blood of subjects

    Time frame: Minimum of 2 years post CT103A infusion

Other outcomes

  1. Immunogenicity

    Development of an anti-CAR antibody response

    Time frame: Minimum of 2 years post CT103A infusion

  2. replication competent lentivirus (RCL)

    The incidence of replication competent lentivirus (RCL)

    Time frame: Minimum of 2 years post CT103A infusion

  3. the levels of CAR-T related inflammatory factors

    the levels of CRP, IL-6 and Ferritin

    Time frame: Minimum of 2 years post CT103A infusion

07

Study locations

14 of 14 sites recruiting
  • Anhui Provincial Cancer Hospital
    Hefei, Anhui, China
    Recruiting
    • Kaiyang Ding · Contact
  • The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital
    Zhengzhou, Henan, China
    Recruiting
    • Yongping Song · Contact
  • Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology
    Wuhan, Hubei, China
    Recruiting
    • Chunrui Li · Contact
  • The Third Xiangya Hospital of Central South University
    Changsha, Hunan, China
    Recruiting
    • Jing Liu · Contact
  • Jiangsu Province Hospital, The First Affiliated Hospital of Nanjing Medical University
    Nanjing, Jiangsu, China
    Recruiting
    • Jianyong Li · Contact
  • The Affiliated Hospital of Nanjing University Medical School, Nanjing Drum Tower Hospital
    Nanjing, Jiangsu, China
    Recruiting
    • Bing Chen · Contact
  • The Affiliated Hospital of Xuzhou Medical University
    Xuzhou, Jiangsu, China
    Recruiting
    • Zhenyu Li · Contact
  • The First Affiliated Hospital, Zhejiang University School of Medicine
    Hangzhou, Zhejiang, China
    Recruiting
    • He Huang · Contact
  • Beijing Boren Hospital
    Beijing, China
    Recruiting
    • Kai Hu · Contact
  • Peking University First Hospital
    Beijing, China
    Recruiting
    • Hanyun Ren · Contact
  • Xinqiao Hospital, Army Medical University
    Chongqing, China
    Recruiting
    • Xi Zhang · Contact
  • Fudan University Zhongshan Hospital
    Shanghai, China
    Recruiting
    • Peng Liu · Contact
  • Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
    Shanghai, China
    Recruiting
    • Jianqing Mi · Contact
  • Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
    Tianjin, China
    Recruiting
    • Lugui Qiu · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2020 (actual). Primary completion is estimated for Oct 2022, 30 months after the start.

Of 98 industry-sponsored phase 1/2 interventional studies under Multiple Myeloma, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 90. This study's planned 30 months is below that.

Counting every sponsor, half of 201 studies reached it within 65 months; a quarter within 44 and three quarters within 92.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2021
First posted
Oct 4, 2021
StartActual
Apr 1, 2020
Primary completionEst.
Oct 2022
CompletionEst.
Jun 2024
Last update
Nov 23, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 23, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05066646
Lead sponsor
Nanjing IASO Biotechnology Co., Ltd.
Responsible party
Sponsor
First posted
Oct 4, 2021
Start date
Apr 1, 2020
Primary completion
Oct 2022 (estimated)
Completion
Jun 2024 (estimated)
Last update
Nov 23, 2021

Study contacts

Songbai Cai
Contact
simon@iasobio.com
+86 025-58287610
Lugui Qiu, MD, PhD
principal investigator · Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Chunrui Li, MD, PhD
principal investigator · Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Equecabtagene autoleucel

Start the discussion